Abstract
Oxidant stress [ OS ] is a condition in which cells are exposed to excessive levels of either molecular oxygen or chemical derivatives of oxygen called reactive oxygen species [ROS], principal amongst which is superoxide [O2 -]. It is becoming increasingly apparent that O2 - is a key risk factor for cardiovascular disease [CVD], including atherogenesis, reperfusion injury, angina, restenosis following balloon angioplasty and vein graft failure. When one considers the multiplicity of effects of O2 -, this is perhaps not surprising, as it promotes vascular smooth muscle cell proliferation, damages the endothelium, promotes lipid oxidation and activates blood cells. However, perhaps the key reaction of O2 - is that with nitric oxide [NO] to form peroxynitrite [ONOO] resulting in a depletion of endogenous vascular NO. Reduced NO formation is also now firmly associated with the aetiology of CVD and as such NO donors may become a major class of drugs. Furthermore, risk factors for CVD, in particular diabetes mellitus [DM], dyslipidaemia, and hyperhomocysteinaemia are all associated with OS. As such, it is becoming increasingly apparent that novel antioxidant therapies, including the gene transfer of antioxidant enzymes, are potentially valuable in the treatment of CVD. In this review, the aetiology of OS and CVD is discussed with particular emphasis on NO. The interactions of risk factors and how this pathophysiology relates to the design of effective novel strategies to treat CVD is also considered. Particular emphasis is also placed on OS and cardiovascular surgery.
Keywords: oxidative stress, nitric oxide, vascular disease, cardiovascular surgery
Current Vascular Pharmacology
Title: Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Volume: 2 Issue: 3
Author(s): Jamie Y. Jeremy, Nilima Shukla, Saima Muzaffar, Alexandra Handley and Gianni D. Angelini
Affiliation:
Keywords: oxidative stress, nitric oxide, vascular disease, cardiovascular surgery
Abstract: Oxidant stress [ OS ] is a condition in which cells are exposed to excessive levels of either molecular oxygen or chemical derivatives of oxygen called reactive oxygen species [ROS], principal amongst which is superoxide [O2 -]. It is becoming increasingly apparent that O2 - is a key risk factor for cardiovascular disease [CVD], including atherogenesis, reperfusion injury, angina, restenosis following balloon angioplasty and vein graft failure. When one considers the multiplicity of effects of O2 -, this is perhaps not surprising, as it promotes vascular smooth muscle cell proliferation, damages the endothelium, promotes lipid oxidation and activates blood cells. However, perhaps the key reaction of O2 - is that with nitric oxide [NO] to form peroxynitrite [ONOO] resulting in a depletion of endogenous vascular NO. Reduced NO formation is also now firmly associated with the aetiology of CVD and as such NO donors may become a major class of drugs. Furthermore, risk factors for CVD, in particular diabetes mellitus [DM], dyslipidaemia, and hyperhomocysteinaemia are all associated with OS. As such, it is becoming increasingly apparent that novel antioxidant therapies, including the gene transfer of antioxidant enzymes, are potentially valuable in the treatment of CVD. In this review, the aetiology of OS and CVD is discussed with particular emphasis on NO. The interactions of risk factors and how this pathophysiology relates to the design of effective novel strategies to treat CVD is also considered. Particular emphasis is also placed on OS and cardiovascular surgery.
Export Options
About this article
Cite this article as:
Jeremy Y. Jamie, Shukla Nilima, Muzaffar Saima, Handley Alexandra and Angelini D. Gianni, Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery, Current Vascular Pharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570161043385691
DOI https://dx.doi.org/10.2174/1570161043385691 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
White Matter Neuroprotection in Preterm Infants
Current Pediatric Reviews Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Vascular Pharmacology Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Synthesis and Biological Activity of the Pyridine-hexacyclic-steroid Derivative on a Heart Failure Model
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Regulation of Inflammatory Responses by Sensory Neurons: Molecular Mechanism(s) and Possible Therapeutic Applications
Current Medicinal Chemistry Fish and Apoptosis: Molecules and Pathways
Current Pharmaceutical Design Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Berberine Ameliorates Cognitive Impairment by Regulating Microglial Polarization and Increasing Expression of Anti-inflammatory Factors following Permanent Bilateral Common Carotid Artery Occlusion in Rats
CNS & Neurological Disorders - Drug Targets Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Prostacyclin Synthase Gene: Genetic Polymorphisms and Prevention of Some Cardiovascular Diseases
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Oxidative Stress in Hepatic Ischemia-Reperfusion Injury: The Role of Antioxidants and Iron Chelating Compounds
Current Pharmaceutical Design Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design